The role of thalidomide in the treatment of rheumatic disease

Journal of Clinical Rheumatology

Volumn 6, Issue 1, 2000, Pages 19-26

  Lenardo, Timothy M ^a   Calabrese, Leonard H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti angiogenic; Immunomodulatory; Peripheral neuropathy; Refractory anti inflammatory; Rheumatic disease; Teratogenic; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; BEHCET DISEASE; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GENITAL ULCER; INFLAMMATORY DISEASE; MOUTH ULCER; NEUROTOXICITY; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN LUPUS ERYTHEMATOSUS; TERATOGENICITY;

EID: 0034005487     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-200002000-00003     Document Type: Article

References (51)

1. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering Thalidomide: A review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35:969-79.
2. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy with case reports of congenital anomalies. New Engl J Med 1962;267:1184-93.
3. Sheskin, J. Thalidomide in the treatment of leprous reactions. Clin Pharmacol Ther 1965; 6:303-6.
4. Chen T-L, Vogelsang GB, Petty BG, Brundarett RB, Noe DA, Santos GW et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos Biol 1989;17:402-5.
5. Schumacher H R, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25: 338-351.
6. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocyte chemotaxis by thalidomide. Arch Dermatol Res 1980;269:275-80.
7. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-21.
8. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorpho-nuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:814-9.
9. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173: 699-703.
10. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kapkin G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
11. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral apthous ulcers in patients with human immunodeficiency virus infection. New Engl J Med 1997;336:1487-93.
12. Kaplan G, Schambelan M, Gottlieb M et. al. Thalidomide reverses cachexia in HIV-wasting syndrome [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; Chicago, IL 1998; no. 476.
13. Wolkenstein P, Latarjet JRJC, Duguet C, Bondeau S, Vaillant L, Maignan M et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
14. Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-92.
15. D' Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. PNAS 1994;91:4082-5.
16. Calabrese L, Resztak K. Thalidomide revisited: pharmacology and clinical applications. Curr Opin Rheumatol. In press 1998.
17. Jorizzo JL, Schmalstieg FC, Solomon AR, Cavallo T, Taylor RS, Rudloff HB, et al. Thalidomide effects in Behcet's Syndrome and pustular vasculitis. Arch Intern Med 1986;146: 878-81.
18. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's syndrome: a randomized, double-blind, placebo controlled trial. Ann Intern Med 1998;128:443-50.
19. Saylan T, Saltik I. Thalidomide in the treatment of Behcet's syndrome [letter]. Arch Dermatol 1982;118:536.
20. Hamza MH. Treatment of Behcet's disease with thalidomide. Clin Rheumatol 1986:5:365-71.
21. Bonnetblanc JM, Royer C, Bedane C. Thalidomide and recurrent apthous stomatitis: a follow-up study. Dermatology 1996;193:321-3.
22. Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
23. Ramselaar CG, Boone RM, Kluin-Nelemans HC. Thalidomide in the treatment of neuro-Behcet's syndrome. Br J Dermatol 1986;115: 367-70.
24. Hasper MF. Chronic cutaneous lupus erythematosus: thalidomide treatment of eleven patients. Arch Dermatol 1983;119:812-15.
25. Scolari F, Harms M, Gilardi S. Thalidomide in the treatment of chronic lupus erythematosus. Dermatologica 1982;165:355-62.
26. Naafs B, Bakkers EJ, Flinterman J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982;107: 83-6.
27. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108: 461-6.
28. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11: 487-93.
29. Stevens RJ, Anderjar C, Edwards CJ, Ames PRJ, Barwick AR, Kamsishta MA, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997;36:355-9.
30. Gutierrez-Rodriguez O. Thalidomide a promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984;27:1118-21.
31. Huizinga TWJ, Dijkmans BAC, van der Velde EA, van de Pouw Kraan TCTM, Verweij CL, Breedveld FC. An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996;55:833-6.
32. Scoville CD. Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis (abstract). Arthritis Rheum 1998; 41(9 Suppl):S60.
33. Scoville CD, Reading JC. Open trial of thalidomide in the treatment of rheumatoid arthritis. J Clin Rheumatol 1999;1:261-7.
34. Oliver SJ, Moreira A, Ozawa M, Krueger JG, Kaplan G. Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response. Arthritis Rheum 1999;42 Suppl:S277.
35. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866-89.
36. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998;39:835-8.
37. Mavilia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
38. Oliver SJ, Moreira A, Kaplan G. Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. Arthritis Rheum 1999;42(Suppl):S187.
39. Stambe C, Wicks IP. TNFα and response of treatment-resistant adult-onset Still's disease to thalidomide [letter]. Lancet 1998;352:544-5.
40. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis [letter]. Arthritis Rheum 1999;42:580-1.
41. Neubert R, Neubert D. Peculiarities and possible mode of action of thalidomide: born GVR. In: Cuatrecasas P, Gauten D, Merken H, Melmon KL, editors. Handbook of Experimental Pharmacology. New York: Springer-Verlag; 1996;124.2:41-120.
42. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
43. Mitchell AA, Van Bennekom CM, Louik C. Pregnancy prevention program in women of child bearing age receiving isotretinoin. New Engl J Med 1995;333:101-6.
44. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984;120:338-41.
45. Fullerton PM, O' Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological and histological follow-up study. J Neurol Neurosurg Psychiatry 1968;31:543-51.
46. Ordi J, Cortes F, Martinez N, Mauri M, De Torres I, Vilardell M. Thalidomide induces amenorrhea in patients with lupus disease [letter]. Arthritis Rheum 1998;41:2273-5.
47. Hess CW, Hunziker T, Kupfer A, Ludin HP. Thalidomide-induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233:83-9.
48. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, et al. Selection of novel analogues of thalidomide with enhanced tumor necrosis alpha inhibitor activity. Molec Med 1996;2:506-15.
49. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, et al. CC-3052: a water-soluble analogue of thalidomide and potent inhibitor of activation-induced TNFα production. J Immunol 1998;161:4236-43.
50. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-61.
51. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985;56:35-9.